Menopause Practice Questions

Q: Hormone Replacement Therapy (HRT) in postmenopausal women is beneficial in all these except

Prevention of CAD. ***Prevention of CAD*** - While HRT was initially thought to be cardioprotective, large-scale studies like the **Women's Health Initiative (WHI)** demonstrated that it does **not prevent coronary artery disease (CAD)** and may even increase the risk of cardiovascular events, especially in older postmenopausal women or those initiating therapy years after menopause. - The potential benefits regarding CAD prevention are outweighed by risks such as **stroke** and **venous thromboembolism**. *Vaginal atrophy* - **Estrogen deficiency** in postmenopausal women leads to thinning, dryness, and inflammation of the vaginal walls, causing symptoms like dryness, irritation, and painful intercourse. - **Local or systemic estrogen therapy** effectively reverses these changes by restoring vaginal tissue health. *Osteoporosis* - **Bone loss** accelerates after menopause due to declining estrogen levels, increasing the risk of osteoporosis and fractures. - HRT, particularly estrogen, is effective in **preventing and treating osteoporosis** by inhibiting bone resorption and preserving bone mineral density. *Vasomotor symptoms* - **Hot flashes** and **night sweats** are common and often debilitating symptoms of menopause, directly linked to fluctuating and declining estrogen levels. - HRT, especially systemic estrogen, is the **most effective treatment** for alleviating these symptoms by stabilizing thermoregulatory control.

Q: A 46-year-old woman presents for her annual examination. Her main complaint is frequent sweating episodes with a sensation of intense heat starting at her upper chest and spreading up to her head. These have been intermittent for the past 6 to 9 months but are gradually worsening. She has three to four flushing/sweating episodes during the day and two to three at night. She occasionally feels her heart race for about a second, but when she checks her pulse it is normal. She reports feeling more tired and has difficulty with sleep due to sweating. She denies major life stressors. She also denies weight loss, weight gain, or change in bowel habit. Her last menstrual cycle was 3 months ago. Physical examination is normal. Which treatment is most appropriate in alleviating this woman's symptoms?

Estrogen plus progesterone. ***Estrogen plus progesterone*** - This patient's symptoms (hot flashes, night sweats, fatigue, sleep disturbance, irregular menses) are highly suggestive of **perimenopause/menopause**. **Hormone replacement therapy (HRT)** with estrogen and progesterone is the most effective treatment for managing severe menopausal symptoms. - Adding **progesterone** is crucial for women with an intact uterus to prevent **endometrial hyperplasia** and **endometrial cancer** caused by unopposed estrogen therapy. *Citalopram* - **Selective serotonin reuptake inhibitors (SSRIs)** like citalopram can reduce the frequency and severity of hot flashes, but they are generally reserved for women who cannot take or prefer not to take HRT due to contraindications or concerns. - SSRIs are less effective than HRT for severe vasomotor symptoms and do not address other menopausal symptoms like vaginal dryness or bone loss. *Estrogen* - While estrogen is the primary hormone for alleviating menopausal symptoms, administering **unopposed estrogen** to a woman with an intact uterus significantly increases the risk of **endometrial hyperplasia** and **endometrial carcinoma**. - Progesterone is necessary to counteract the proliferative effects of estrogen on the endometrium, preventing these risks. *Levothyroxine* - **Levothyroxine** is used to treat **hypothyroidism**, a condition that can cause fatigue, weight changes, and menstrual irregularities. - However, the patient's primary symptoms of prominent hot flashes and night sweats are not characteristic of hypothyroidism, and her physical examination is normal, making this diagnosis less likely.

Q: Menopausal hot flushes occur due to

Decrease in estrogen. ***Decrease in estrogen*** - **Decreased estrogen** levels in menopause lead to a narrowing of the **thermo-neutral zone**, causing the body to be more sensitive to small changes in core body temperature. - This hormonal withdrawal results in **vasodilation** and a sensation of heat, culminating in a hot flush. *FSH secretion* - While **FSH (Follicle-Stimulating Hormone)** levels do increase significantly during menopause due to reduced negative feedback from estrogen, FSH itself does not directly cause hot flushes. - The elevated FSH is a consequence of ovarian failure and is a marker of menopause, but the primary cause of hot flashes is the estrogen withdrawal. *Increase in progesterone* - **Progesterone levels actually decline** during menopause as ovulation ceases. - An increase in progesterone is not associated with hot flushes; rather, cyclical progesterone therapy can sometimes mitigate symptoms in certain hormonal contexts. *Increase in estrogen* - Hot flushes are a hallmark symptom of **estrogen deficiency**, not an increase in estrogen. - Conditions involving increased estrogen (e.g., pregnancy or certain tumors) would not typically present with menopausal hot flushes.

Q: Absolute contraindication of hormone replacement therapy is:

Thrombosis. ***Thrombosis*** - A history of **thrombosis** (e.g., DVT, pulmonary embolism) is an **absolute contraindication** to hormone replacement therapy (HRT) due to the increased risk of further **thromboembolic events**, as estrogen can promote coagulation [1], [2]. - HRT can increase the risk of **blood clot formation**, making it unsafe for individuals with a prior or current thrombotic condition [1]. *Fibroadenoma* - **Fibroadenomas** are **benign breast lumps** and are generally not considered an absolute contraindication for HRT. - While HRT can potentially cause some **breast density** changes, fibroadenomas do not typically preclude its use, though monitoring may be advised. *Fibrocystic disease* - **Fibrocystic breast disease** is a common **benign breast condition** characterized by lumpy, tender breasts, and it is **not an absolute contraindication** for HRT. - HRT might occasionally exacerbate breast tenderness in some women with fibrocystic changes, but it does not pose a severe health risk. *Hemorrhage* - Acute or uncontrolled **vaginal hemorrhage**, especially of undetermined etiology, is a contraindication to initiating HRT until the cause is identified and managed. - However, once the hemorrhage is controlled and its cause is determined not to be uterine cancer, previous hemorrhage itself is **not an absolute contraindication** to long-term HRT.

Q: Which of the following is NOT effective in controlling the hot flushes of menopause in a woman?

Raloxifene. ***Raloxifene*** - **Raloxifene** is a selective estrogen receptor modulator (SERM) that acts as an estrogen agonist in bone tissue, helping to prevent osteoporosis, but it is an estrogen antagonist in other tissues and can actually worsen or induce **hot flushes**. - Its primary indications are for the prevention and treatment of **osteoporosis** in postmenopausal women, and for the reduction of risk of invasive breast cancer in high-risk women. *Isoflavones* - **Isoflavones** (e.g., from soy) are phytoestrogens that can have weak estrogenic effects, and some women find them helpful in reducing the frequency and severity of **hot flushes**, though efficacy varies. - They bind to estrogen receptors, potentially mitigating the sudden drops in estrogen that lead to **vasomotor symptoms**. *Hormone replacement therapy* - **Hormone replacement therapy (HRT)**, which involves estrogen with or without progestin, is the most effective treatment for **menopausal hot flushes**. - By replacing declining estrogen levels, HRT directly addresses the underlying cause of **vasomotor instability**. *Tibolone* - **Tibolone** is a synthetic steroid that has estrogenic, progestogenic, and androgenic properties, and it is effective in relieving **menopausal hot flushes**. - It specifically targets estrogen receptors in the hypothalamus, which helps to stabilize **thermoregulatory control** and reduce hot flushes.

Q: Hormone replacement therapy (HRT) is indicated in:

Osteoporosis. ### Osteoporosis - **Hormone replacement therapy (HRT)** is indicated for the prevention and treatment of **osteoporosis** in postmenopausal women, especially when other therapies are unsuitable [1]. - Estrogen, a component of HRT, helps maintain **bone mineral density** by decreasing bone resorption and increasing bone formation. *previous history of thromboembolic episode* - A previous history of **thromboembolic events**, such as deep vein thrombosis or pulmonary embolism, is a **contraindication** for HRT. - HRT can increase the risk of **blood clot formation**, making it unsafe for individuals with such a history. *women with uterine cancer* - Women with **uterine cancer**, particularly **endometrial cancer**, should generally avoid HRT containing estrogen. - Estrogen can stimulate the growth of **endometrial cells**, potentially worsening uterine cancer or increasing its recurrence risk [1]. *women with breast cancer* - **Breast cancer** is a strong **contraindication** for HRT, especially estrogen-containing regimens [1]. - Estrogen can promote the growth of **hormone-sensitive breast cancer cells**, increasing the risk of recurrence or progression.

Q: Senile vaginitis is due to :

Oestrogen deficiency. ***Oestrogen deficiency*** - **Senile vaginitis**, also known as **atrophic vaginitis**, is primarily caused by **decreased oestrogen levels**, particularly after menopause. - Reduced oestrogen leads to thinning and drying of the vaginal walls, making them more susceptible to inflammation and infection. *Diabetes* - While uncontrolled **diabetes** can increase the risk of vaginal infections, such as **candidiasis**, it is not the direct cause of senile vaginitis itself. - Diabetic neuropathy can affect vaginal sensation, but does not cause the atrophic changes observed in senile vaginitis. *Gonococcal infection* - **Gonococcal infection** is a sexually transmitted infection that causes acute inflammation of the mucous membranes, but not the long-term atrophic changes seen in senile vaginitis. - It would present with purulent discharge and dysuria, which are distinct from the symptoms of senile vaginitis. *Cancer cervix* - **Cervical cancer** is a malignancy of the cervix and does not directly cause senile vaginitis. - While it can manifest with abnormal vaginal bleeding or discharge, these symptoms are typically due to the tumor itself and not the atrophic changes characteristic of senile vaginitis.

Q: A female is on hormone replacement therapy for her menopausal symptoms. She is worried about her bone strength because her mom and sister had osteoporosis after the age of 50. All are given for prevention of osteoporosis along with hormonal replacement therapy, EXCEPT:

Vitamin-E. ***Vitamin-E*** - **Vitamin-E** is an **antioxidant** vitamin that primarily protects cells from oxidative damage. - It does not play a direct role in **bone metabolism** or the prevention of osteoporosis. *Calcium* - **Calcium** is a fundamental component of bone tissue and is essential for maintaining **bone density** [1]. - Adequate calcium intake is crucial for **osteoporosis prevention**, especially in postmenopausal women [1], [2]. *Vit.D* - **Vitamin D** is essential for **calcium absorption** in the gut and its incorporation into bones. - Without sufficient Vitamin D, calcium cannot be effectively utilized, leading to compromised **bone health**. *None of the options* - This option is incorrect because Vitamin E does not contribute to osteoporosis prevention, making it the correct answer to the "EXCEPT" question. - Calcium and Vitamin D are both vital for bone strength, so stating that none of the options fit would be inaccurate [1].

Q: For a menopausal patient having hot flashes, which of the following can be given as treatment?

17β-estradiol. ***17β-estradiol*** - **Estrogen therapy** is the **gold standard** and **most effective treatment** for menopausal vasomotor symptoms including hot flashes - **17β-estradiol** directly replaces the declining ovarian estrogen levels that cause hot flashes - Recommended by all major guidelines (NAMS, ACOG, IMS) as **first-line therapy** for moderate to severe vasomotor symptoms - Available in various formulations: oral, transdermal patches, gels, and sprays - In women with an intact uterus, progestogen must be added to prevent endometrial hyperplasia *Progesterone* - **Progestogens** (synthetic progesterone) are primarily used to **protect the endometrium** when estrogen is prescribed to women with an intact uterus - Can provide **mild relief** of hot flashes in some women, but are **significantly less effective** than estrogen therapy - May be considered as **monotherapy** only when estrogen is contraindicated (e.g., breast cancer, thromboembolic disease) - **Not first-line treatment** for vasomotor symptoms *Danazol* - An **attenuated androgen** with anti-estrogenic and androgenic properties - Used primarily for **endometriosis** and **fibrocystic breast disease** - Would **worsen menopausal symptoms** including hot flashes due to its anti-estrogenic effects - Contraindicated in menopause management *Gonadotropin* - **FSH and LH** levels are already **markedly elevated** in menopause due to lack of negative feedback from ovarian hormones - Used in **fertility treatment**, not menopausal symptom management - Exogenous gonadotropin administration is **inappropriate and ineffective** for hot flashes

Question 1

Hormone Replacement Therapy (HRT) in postmenopausal women is beneficial in all these except

Accepted Answer

Prevention of CAD

Answer

Vaginal atrophy

Answer

Osteoporosis

Answer

Vasomotor symptoms

Question 2

A 46-year-old woman presents for her annual examination. Her main complaint is frequent sweating episodes with a sensation of intense heat starting at her upper chest and spreading up to her head. These have been intermittent for the past 6 to 9 months but are gradually worsening. She has three to four flushing/sweating episodes during the day and two to three at night. She occasionally feels her heart race for about a second, but when she checks her pulse it is normal. She reports feeling more tired and has difficulty with sleep due to sweating. She denies major life stressors. She also denies weight loss, weight gain, or change in bowel habit. Her last menstrual cycle was 3 months ago. Physical examination is normal. Which treatment is most appropriate in alleviating this woman's symptoms?

Accepted Answer

Estrogen plus progesterone

Answer

Citalopram

Answer

Estrogen

Answer

Levothyroxine

Question 3

Menopausal hot flushes occur due to

Accepted Answer

Decrease in estrogen

Answer

FSH secretion

Answer

Increase in progesterone

Answer

Increase in estrogen

Question 4

Absolute contraindication of hormone replacement therapy is:

Accepted Answer

Thrombosis

Answer

Fibroadenoma

Answer

Fibrocystic disease

Answer

Hemorrhage

Question 5

Which of the following is NOT effective in controlling the hot flushes of menopause in a woman?

Accepted Answer

Raloxifene

Answer

Isoflavones

Answer

Hormone replacement therapy

Answer

Tibolone

Question 6

Hormone replacement therapy (HRT) is indicated in:

Accepted Answer

Osteoporosis

Answer

previous history of thromboembolic episode

Answer

women with uterine cancer

Answer

women with breast cancer

Question 7

Senile vaginitis is due to :

Accepted Answer

Oestrogen deficiency

Answer

Diabetes

Answer

Gonococcal infection

Answer

Cancer cervix

Question 8

A female is on hormone replacement therapy for her menopausal symptoms. She is worried about her bone strength because her mom and sister had osteoporosis after the age of 50. All are given for prevention of osteoporosis along with hormonal replacement therapy, EXCEPT:

Accepted Answer

Vitamin-E

Answer

Calcium

Answer

Vit.D

Answer

None of the options

Question 9

Which of the following is NOT characteristic of menopause?

Accepted Answer

There is a marked decrease in adrenal cortical estrogen secretion

Answer

Systemic vasomotor instability may be present

Answer

There may be an increase in FSH secretion by the pituitary gland

Answer

There is a decrease in skin elasticity

Question 10

For a menopausal patient having hot flashes, which of the following can be given as treatment?

Accepted Answer

17β-estradiol

Answer

Progesterone

Answer

Danazol

Answer

Gonadotropin

Menopause — MCQs

Menopause — MCQs

On this page

Practice by Chapter

Want unlimited practice?